Efficacy of the classical swine fever (CSF) marker vaccine Porcilis Pesti in pregnant sows

The efficacy of the classical swine fever (CSF) subunit marker vaccine Porcilis Pesti based on baculovirus expressed envelope glycoprotein E2 of CSF virus (CSFV) was evaluated in pregnant sows. Ten gilts were vaccinated with one dose of marker vaccine, followed by a second dose 4 weeks later. Four gilts remained unvaccinated and received a placebo at the same times. Thirty-three days after the second vaccination all animals were artificially inseminated. Neither local or systemic reactions nor an increase of body temperature were observed after vaccinations. All gilts showed a normal course of pregnancy. Thirty-five days after first vaccination all animals developed E2 specific neutralising antibodies with titres in the range of 5.0 and 7.5 log(2). No antibodies to CSFV-E(rns) were found in ELISA.On day 65 of gestation (126 days after the first immunisation) all sows were infected intranasally using 2ml (10(6.6) TCID(50)/ml) of the low virulent CSFV strain "Glentorf". After challenge in two of the unvaccinated control sows a slight transient increase of body temperature was observed, whereas leukopenia was demonstrated in all control animals. In addition all controls became viraemic. Vaccinations with the CSFV subunit vaccine protected the animals from clinical symptoms of CSF. In two sows a moderate decrease of leukocyte counts was detected on day 5 post infection. In contrast to the unvaccinated control sows in none of the vaccinated animals virus was isolated from the nasal swabs or the blood.Approximately 40 days after challenge all sows were killed and necropsy was done. The sows and their offspring were examined for the presence of CSFV in blood, bone marrow and different organs. No virus was found in any of the sows. In contrast, in all litters of the control sows CSFV was found in the blood as well as in the organ samples. Nine out of 10 litters of the vaccinated sows were protected from CSFV infection. Blood samples, lymphatic organs and bone marrow of these animals were all virologically negative. When sera were tested for CSFV-antibodies all sows had developed E(rns)-specific antibodies but no CSFV-specific antibodies were found in any of the progeny.It was concluded that vaccination with CSF subunit marker vaccine Porcilis((R)) Pesti protected 90% of the litters from viral infection when sows were challenged mid-gestation using the CSFV-strain "Glentorf".     

Development of a classical swine fever subunit marker vaccine and companion diagnostic test

The development of a classical swine fever (CSF) subunit marker vaccine, based on viral envelope glycoprotein E2, and a companion diagnostic test, based on a second viral envelope glycoprotein E(RNS), will be described. Important properties of the vaccine, such as onset and duration of immunity, and prevention of horizontal and vertical transmission of virus were evaluated. A single dose of the vaccine protected pigs against clinical signs of CSF, following intranasal challenge with 100LD(50) of virulent classical swine fever virus (CSFV) at 2 weeks after vaccination. However, challenge virus transmission to unvaccinated sentinels was not always completely inhibited at this time point. From 3 weeks up to 6 months after vaccination, pigs were protected against clinical signs of CSF, and no longer transmitted challenge virus to unvaccinated sentinels. In contrast, unvaccinated control pigs died within 2 weeks after challenge. We also evaluated transmission of challenge virus in a setup enabling determination of the reproduction ratio (R value) of the virus. In such an experiment, transmission of challenge virus is determined in a fully vaccinated population at different time points after vaccination. Pigs challenged at 1 week after immunization died of CSF, whereas the vaccinated sentinels became infected, seroconverted for E(RNS) antibodies, but survived. At 2 weeks after vaccination, the challenged pigs seroconverted for E(RNS) antibodies, but none of the vaccinated sentinels did. Thus, at 1 week after vaccination, R1, and at 2 weeks, R=0, implying no control or control of an outbreak, respectively. Vertical transmission of CSFV to the immune-incompetent fetus may lead to the birth of highly viraemic, persistently infected piglets which are one of the major sources of virus spread. Protection against transplacental transmission of CSFV in vaccinated sows was, therefore, tested in once and twice vaccinated sows. Only one out of nine once-vaccinated sows transmitted challenge virus to the fetus, whereas none of the nine twice-vaccinated sows did. Finally, our data show that the E(RNS) test detects CSFV-specific antibodies in vaccinated or unvaccinated pigs as early as 14 days after infection with a virulent CSF strain. This indicates that the E2 vaccine and companion test fully comply with the marker vaccine concept. This concept implies the possibility of detecting infected animals within a vaccinated population.     

Classical swine fever virus strain "C" protects the offspring by oral immunisation of pregnant sows

The aim of this study was to evaluate if oral immunisation of wild sows protects the fetuses from transplacental infection. Two experiments were carried out with gilts vaccinated orally with C-strain virus approximately 5 weeks after insemination. They were challenged at mid-gestation with highly virulent classical swine fever virus (CSFV) or moderately virulent field virus. The results revealed that oral vaccination has no negative impact on the pregnancy, and all vaccinated sows developed neutralising antibodies. After infection no symptoms were detected in the six vaccinated-infected sows. Challenge virus could neither be found in blood, nasal and fecal swabs or saliva nor in organs sampled at necropsy. Likewise, all fetuses originating from vaccinated sows were virologically and serologically negative. In contrast, the controls developed a short viremia and as a result of the transplacental infection all fetuses were CSFV positive. In addition, 22 serologically positive wild sows of an endemically infected area, where oral vaccination had also been carried out, and their offspring were free from CSFV or viral RNA. Our results confirm that oral immunisation of pregnant wild sows with C-strain vaccine may protect the fetuses against CSF.     

SEROLOGICAL RESPONSES IN PIGS VACCINATED WITH INACTIVATED PORCINE PARVOVIRUS

The safety and immunogenicity of inactivated porcine parvovirus (PPV) vaccines were investigated. Both beta-propiolactone and formalin successfully inactivated virus without destroying immunogenicity, which was considerably enhanced by incorporation of a gel adjuvant in the vaccine. Using the formalised-gel vaccine, initial antibody responses were demonstrated in susceptible piglets and adult pigs at 7 days after vaccination. These antibody responses persist at significant levels for at least 6 months after vaccination. Antibody levels increased up to 16 fold when revaccination was carried out. Vaccination of gilts with low level (passive) immunity resulted in antibody responses comparable to those recorded in susceptible pigs. The vaccine was safe as determined by absence of residual virus in the vaccine, absence of viraemia and excretion in vaccinted stock, and absence of effect on litters of sows vaccinated at different gestational ages. Vaccine stored at 4 degrees C for 6 months was as immunogenic as fresh vaccine.     

Effect of experimental infection with pseudorabies (Aujeszky's disease) virus on pigs with maternal immunity from vaccinated sows.

Live-virus and inactivated-virus vaccines were used to immunize sows against pseudorabies (Aujeszky's disease) virus. To test the efficacy of the vaccination, 53 pigs of different ages were taken from the 1st and the 2nd litters of vaccinated sows and placed separately in isolation units. The pigs were challenge exposed with virulent pseudorabies virus and examined for clinical signs, virus excretion, and serologic reaction. The challenge inoculum caused severe nervous or respiratory signs of disease in 12 of the 13 control pigs, with a mortality of 76%. The pigs from the 1st litters of sows vaccinated with the live-virus vaccine did not become sick, whereas 2 of the 9 pigs (22%) from the 2nd litters had clinical signs and died of pseudorabies. All pigs from sows vaccinated with the inactivated-virus vaccine remained healthy. The results of virus isolation from oronasal swabs, combined with the serotest results, indicated that challenge exposure of all except 1 of the pigs resulted in a subclinical infection with the formation of active immunity.     

Vaccination of pregnant sows against transmissible gastroenteritis with two attenuated virus strains and different inoculation routes

Summary Two attenuated transmissible gastro-enteritis (T. G. E.) virus strains were used for vaccination experiments in sows. Four different experiments were carried out (see Table 1). In each experiment, 9 sows were vaccinated during pregnancy and 3 sows served as controls. They were kept together in one farrowing house. The sows were due to farrow at about the same time. The sows and their litters were challenged shortly after farrowing by exposing 3 piglets of 2 control litters to virulent TGE virus. The following vaccination schedules were used (see Table 1): twice intramuscularly with TGE-vac (a commercially available TGE-vaccine), one oral administration followed by an intramuscular vaccination with an attenuated TGE Purdue (Pu) strain, twice orally with Pu strain in enteric coated capsules, and one direct intra intestinal administration followed by 2 intramuscular vaccinations or 3 intramuscular vaccinations with the Pu strain. All sows, except most of those treated with enteric coated capsules, seroconverted demonstrably (Table 2). The geometric mean seroneutralization (SN) titer log 2 varied from 4.1 to 7.5 after the first vaccination and from 7.6 to 10 after the second vaccination. None of the vaccination schedules resulted in an effective lactogenic immunity. The morbidity in the piglets was 100% within 3 to 5 days after challenge. The mortality rate varied from 44 to 80% in litters from vaccinated sows and from 71 to 100% in litters from control sows (see Table 3). Clinical signs were observed in 33,3% of the control sows and in 36% of the vaccinated sows. No correlation was found between the titer of SN antibodies in the sera of the piglets and their survival rate (Table 4). A rapid decrease in antibody concentration was observed, during the first week of lactation in milk samples collected from 4 orally and intramuscularly vaccinated sows (Table 5).     

Vaccination of pregnant sows against transmissible gastroenteritis with two attenuated virus strains and different inoculation routes

Summary

Two attenuated transmissible gastro‐enteritis (T. G. E.) virus strains were used for vaccination experiments in sows.

Four different experiments were carried out (see Table 1). In each experiment, 9 sows were vaccinated during pregnancy and 3 sows served as controls. They were kept together in one farrowing house. The sows were due to farrow at about the same time. The sows and their litters were challenged shortly after farrowing by exposing 3 piglets of 2 control litters to virulent TGE virus.

The following vaccination schedules were used (see Table 1): twice intramuscularly with TGE‐vac (a commercially available TGE‐vaccine), one oral administration followed by an intramuscular vaccination with an attenuated TGE Purdue (Pu) strain, twice orally with Pu strain in enteric coated capsules, and one direct intra intestinal administration followed by 2 intramuscular vaccinations or 3 intramuscular vaccinations with the Pu strain.

All sows, except most of those treated with enteric coated capsules, seroconverted demonstrably (Table 2). The geometric mean seroneutralization (SN) titer log 2 varied from 4.1 to 7.5 after the first vaccination and from 7.6 to 10 after the second vaccination.

None of the vaccination schedules resulted in an effective lactogenic immunity. The morbidity in the piglets was 100% within 3 to 5 days after challenge. The mortality rate varied from 44 to 80% in litters from vaccinated sows and from 71 to 100% in litters from control sows (see Table 3). Clinical signs were observed in 33,3% of the control sows and in 36% of the vaccinated sows.

No correlation was found between the titer of SN antibodies in the sera of the piglets and their survival rate (Table 4).

A rapid decrease in antibody concentration was observed, during the first week of lactation in milk samples collected from 4 orally and intramuscularly vaccinated sows (Table 5).     

Prevention of transplacental transmission of moderate-virulent classical swine fever virus after single or double vaccination with an E2 subunit vaccine

The use of a vaccine against classical swine fever virus (CSFV) during an outbreak of CSF should lead to a reduction in the horizontal or vertical transmission of CSFV. The reduction of vertical, i.e. transplacental, transmission of a moderate-virulent strain of CSFV from the sow to its offspring was studied in sows vaccinated once or twice with a CSFV E2 subunit vaccine. Two groups of nine sows were vaccinated with one PD95 dose of the E2 subunit vaccine, approximately four weeks before insemination. A third group of nine inseminated sows served as controls. One group of nine sows were vaccinated again at two weeks after insemination. At ten weeks after the primary vaccination, approximately six weeks after insemination, all 27 sows were challenged intranasally with 10(5) TCID50 of a moderate-virulent strain of CSFV, the Van Zoelen strain. The sows were euthanized at five weeks after challenge, and samples from the sows and fetuses were collected for detection of CSFV. All 27 sows were in gestation at the time of slaughter, CSFV was detected in the fetuses of all unvaccinated sows but it was not detected in any of the samples collected from fetuses of the double-vaccinated sows. Virus was however recovered from the fetuses of one out of nine sows vaccinated once. All the sows, except four double-vaccinated sows, developed CSFV Erns antibodies. Transplacental transmission of CSFV was reduced significantly (p <0.001) in all vaccinated sows. When the results from the experiment were extrapolated to a herd level, it could be concluded that, with 95% certainty, approximately 11% (single vaccination) or 0% (double vaccination), confidence intervals of 0.01-0.44 and 0.0-0.30 respectively, of the pregnant sows would still not be protected against vertical transmission of moderate-virulent CSFV. We conclude that vaccination with the CSFV E2 subunit vaccine can reduce the transmission of moderate-virulent strain of CSFV from the sow to its offspring significantly.     

Foetal protection against bovine virus diarrhoea virus after two-step vaccination

In order to assess the efficacy of a two-step vaccination protocol with respect to foetal protection against transplacental infections with bovine virus diarrhoea virus (BVDV) with special attention to BVDV-2 seronegative heifers were vaccinated with an inactivated BVDV-1 vaccine and boostered with a modified live BVDV-1 vaccine after 4 weeks. A second group was left unvaccinated as control. Between days 30 and 120 of pregnancy the heifers of both groups were intranasally challenged with a mixture of BVDV-1 and -2. All heifers of the vaccinated group gave birth to nine clinically healthy, seronegative (precolostral) and BVDV-free calves. In contrast in the control group four BVDV viraemic underdeveloped calves were born. Additionally, one calf was stillborn and another viraemic calf was not viable and died 2 days after birth. All six calves of the control group were viraemic with BVDV-2. This study demonstrated for the first time that two-step vaccination of breeding cattle with a modified live BVDV vaccine 4 weeks after application of an inactivated BVDV vaccine was capable of providing a foetal protection against transplacental infection with BVDV-2.     

Foetal Protection against Bovine Virus Diarrhoea Virus after Two‐step Vaccination

In order to assess the efficacy of a two‐step vaccination protocol with respect to foetal protection against transplacental infections with bovine virus diarrhoea virus (BVDV) with special attention to BVDV‐2 seronegative heifers were vaccinated with an inactivated BVDV‐1 vaccine and boostered with a modified live BVDV‐1 vaccine after 4 weeks. A second group was left unvaccinated as control. Between days 30 and 120 of pregnancy the heifers of both groups were intranasally challenged with a mixture of BVDV‐1 and ‐2. All heifers of the vaccinated group gave birth to nine clinically healthy, seronegative (precolostral) and BVDV‐free calves. In contrast in the control group four BVDV viraemic underdeveloped calves were born. Additionally, one calf was stillborn and another viraemic calf was not viable and died 2 days after birth. All six calves of the control group were viraemic with BVDV‐2. This study demonstrated for the first time that two‐step vaccination of breeding cattle with a modified live BVDV vaccine 4 weeks after application of an inactivated BVDV vaccine was capable of providing a foetal protection against transplacental infection with BVDV‐2.     

Evaluation of safety and efficacy of DNA vaccines against bovine herpesvirus-1 (BoHV-1) in calves

Four DNA vaccines against BoHV-1 were evaluated for their efficacy in calves. Twelve animals were divided into four groups which were injected with four different DNA vaccines: pVAX-tgD (Vaccine A); pVAX-tgD co-immunised with pVAX-48CpG (Vaccine B); pVAX-UbiLacI-tgD-L (Vaccine C); pVAX-UbiLacI-tgD-L co-immunised with pVAX-48CpG (Vaccine D). Three additional calves were given the plasmid vector and served as controls. Ninety days after the first vaccination all calves were challenge infected with BoHV-1.All animals developed a severe form of infections bovine rhinotracheitis. Only the calves given the pVAX-tgD co-immunised with pVAX-48CpG (Vaccine B) developed humoral antibodies against BoHV-1 between 56 and 90 days after the first vaccination, whereas in calves of other groups and in the controls, antibodies appeared only after the infection. In the calves vaccinated with either pVAX-tgD (Vaccine A) or pVAX-tgD combined with pVAX-48CpG (Vaccine B), BoHV-1-specific IFN-γ secreting cells were detected in PBMCs 90 days after the first vaccination and their number increased after challenge exposure. In the other groups the IFN-γ secreting cells were detected after virus infection and at low values.     

Clinical evaluation of transmissible gastroenteritis virus vaccines and vaccination procedures for inducing lactogenic immunity in sows

Two federally licensed attenuated live transmissible gastroenteritis (TGE) virus vaccines (an IM vaccine and an oral-IM vaccine) and 1 nonlicensed nonattenuated live TGE virus vaccine were evaluated and compared in sows free of TGE virus-neutralizing antibodies. Litters from the sows were challenge exposed at 3 and 5 days of age, and results were combined according to the vaccine administered to the sows. The survivability of pigs suckling sows vaccinated with the nonattenuated vaccine was significantly (P less than 0.01) greater than that of pigs suckling sows vaccinated with the IM attenuated vaccine, significantly (P less than 0.05) greater than that of pigs suckling sows vaccinated with the oral-IM attenuated vaccine, and significantly (P less than 0.05) greater than that of pigs suckling sows that had not been vaccinated. The differences, however, between survivability of litters from sows vaccinated with the IM attenuated vaccine or the oral-IM attenuated vaccine and that of litters from the sows not vaccinated were not significant (P greater than 0.10). The nonattenuated TGE vaccine, although giving a higher level of protection than the attenuated vaccine, was eventually overwhelmed. Dexamethasone did not increase the incidence of diarrhea, and levamisole did not potentiate the lactogenic immunity in sows after given their first dose of the nonattenuated vaccine. Survivability in litters suckling sows that developed diarrhea after given their first dose of the nonattenuated vaccine was not greater than that in litters suckling sows that did not develop diarrhea. The best results were obtained when 3-day-old suckling pigs were challenge exposed with virulent TGE virus.     

Adsorption of colostral antibodies against classical swine fever, persistence of maternal antibodies, and effect on response to vaccination in baby pigs.

OBJECTIVE: To determine kinetics of antibody absorption, persistence of antibody concentrations, and influence of titers on vaccination of baby pigs with a vaccine against classical swine fever (CSF). ANIMALS: 15 sows and their litters. PROCEDURE: Farrowings were supervised. Initial time of suckling was recorded. In the first experiment, blood samples were collected at farrowing, 2 and 4 hours after suckling, and hourly until 10 hours after initial suckling. Samples were assayed for CSF antibodies, using a serum neutralizing (SN) test. A second experiment included 33 baby pigs vaccinated as follows: 10 prior to ingestion of colostrum, 18 between 1 and 4 hours after ingestion of colostrum, and 5 at 12 hours after ingestion of colostrum. Fourteen pigs were vaccinated when 7 weeks old, and 15 pigs were not vaccinated. At 10 weeks of age, pigs were challenge-exposed with virulent CSF virus. Blood samples were collected and assayed for CSF antibodies and p125 antigen and p125 antibodies. RESULTS: CSF antibodies were detected in pigs beginning 2 hours after suckling. Colostral antibodies persisted for > 7 weeks (half-life, 79 days). Vaccination of pigs before suckling provided effective protection from severe disease after challenge-exposure. However, vaccination of neonates with antibody titers was not effective, because 19 of 23 (82%) pigs succumbed after challenge-exposure. All pigs vaccinated when 7 weeks old resisted challenge-exposure, whereas all unvaccinated control pigs succumbed. CONCLUSIONS AND CLINICAL RELEVANCE: Vaccination before ingestion of colostrum conferred good protection against CSF in baby pigs. Vaccination of 7-week-old pigs that had decreasing concentrations of passively acquired antibodies was efficacious.     

Epidemiological survey of viral diseases of pigs in the Mekong delta of Vietnam between 1999 and 2003

In the Mekong delta, backyard pig rearing plays an integral role in recycling nutrients in farming systems and generating valuable cash income. However, development has been hampered by fatal epizootics of piglets and reproductive failure of sows. Diseases are named by symptoms and blindly treated with antibiotics. As antibiotics are often ineffectual, involvement of viral diseases are suspected. To identify the causative agent, we first sero-surveyed porcine reproductive and respiratory syndrome (PRRS) and pseudorabies with 478 sera from non-vaccinated pigs collected from backyard farms, state farms and slaughterhouses in Can Tho province between 1999 and 2002. Antibodies for PRRS were first detected in 2002 in backyard farms and at high prevalence in state farms with increased piglet mortality. A few backyard breeder pigs had antibodies for pseudorabies in 2000 and 2002. With compulsory classical swine fever (CSF) vaccination, we examined the relationship between vaccination and antibodies in 70 serum samples. Seventy-nine percent of vaccinated breeders had CSF antibodies-higher than expected with irregular vaccination. Since circulation of CSF virus was suspected, isolation was attempted at 10 farms with fatal epizootics between 2002 and 2003. The viruses were detected at all farms and clustered within genogroup 2, despite vaccines corresponding to genogroup 1. This study demonstrated virologically/serologically the existence of PRRS, pseudorabies and CSF viruses in the Mekong delta of Vietnam. We also identified CSF as a cause of piglet mortality that disastrously affected backyard farming. Vaccine standardization and proper instructions are needed to simplify diagnosis and complement established simultaneous vaccination of sows with piglets.     

Safety and efficacy of a classical swine fever subunit vaccine in pregnant sows and their offspring

In the study three groups with five pregnant sows each were used. The animals were vaccinated twice, 2 weeks apart, in different stages of gestation, i.e. +/-4, +/-8 and +/-12 weeks after insemination and then 14 days later, respectively. From each group of sows three litters were randomly selected and vaccinated twice, 4 weeks apart, at 5 and 9, 7 and 11, and 9 and 13 weeks of life, respectively. Blood for serological investigations by virus neutralisation test and ELISA tests (for E(rns) antibodies and for E2 antibodies, separately) was taken before immunisation, at each vaccination and 2 weeks thereafter. Clinical observations shown that no local nor systemic reactions as well as no adverse effect on gestation occurred after vaccinations in any of the sows. Serological tests detected a low level of antibodies after the first vaccination and a typical booster effect after the second one. In piglets no adverse effect of the vaccination on the body weight gain was found. The presence of maternally derived antibodies (MDA) in non-vaccinated control piglets was observed up to the age of 5-13 weeks of life. The most evident immunological reaction was obtained in piglets vaccinated at the age of 5 or 7 weeks of life and revaccinated 4 weeks later. The CSFV-E2 subunit marker vaccine tested proved to be safe for pregnant sows and immunogenic for MDA positive piglets.     

Vaccination of weaner pigs against classical swine fever with the subunit vaccine "Porcilis Pesti": influence of different immunization plans on excretion and transmission of challenge virus

Excretion and transmission of CSFV after vaccination with the CSF subunit marker vaccine "Porcilis Pesti" have been studied using the following different vaccination schedules: Group A--two vaccinations with an interval of 28 d, challenge 14 d after second vaccination (p.v2.); group B--two vaccinations with an interval of 14 d, challenge 14 d later; group C--two vaccinations with an interval of 28 d, challenge at time of booster vaccination; group D--two vaccinations with an interval of 14 d, challenge 7 d p.v2.; group E--single vaccination and infection 14 d later. After infection one sentinel pig was added to the vaccinated and infected pigs of each group. A single vaccination did not induce protective immunity against a CSFV challenge. Double vaccination at a four-week interval protected piglets from clinical infection, and neither viraemia and leukopenia nor virus excretion were detected if infected 14 d p.v2. Two vaccinations at a two-week interval followed by a challenge 7 d p.v2. led to a short viraemia on day 5 p.i. but without excretion of CSFV. Though all other vaccination schedules induced a reduction in virus shedding and a decrease in CSFV replication, in all these cases in-contact controls became infected. The results of transmission of CSFV are discussed in relation to a potential use of subunit marker vaccines in CSF control.     

Immune response of sows and their offspring to pseudorabies virus: serum neutralization response to vaccination and field virus challenge.

One month prior to breeding, sows were vaccinated with an attenuated pseudorabies virus vaccine or challenged with a field strain of pseudorabies virus. A third group of sows were not vaccinated or challenged before breeding. Pigs from these sows were vaccinated at 3, 6, or 12 weeks of age and challenged with virulent virus three weeks later. One pig from each litter served as an unvaccinated, unchallenged control. Serum neutralization titers of these pigs were monitored from birth until 22 weeks of age. Titers of the sows were monitored through breeding, gestation and farrowing. The maximum prefarrowing anti-pseudorabies virus titer in the field virus challenged sows occurred four weeks following challenge. A significant decline in titers occurred at farrowing. Titers rose from one week postfarrowing and then declined. Titers in the field virus infected sows were consistently two to threefold greater than those of the vaccinated sows. The maximum prefarrowing anti-pseudorabies virus titer in the vaccinated sows occurred six weeks following vaccination. The geometric mean titer in these sow's then decreased and increased for two weeks after farrowing. The results in the pigs can be summarized as follows: Pigs from control sows had a greater serological response following field virus challenge than following vaccination with a modified live virus. Pigs from control sows responded serologically to vaccination at 3, 6 and 12 weeks of age. Pigs from control sows which were challenged at 6, 9 and 15 weeks of age had similar antibody responses. Pigs from vaccinated sows had no increase in titer following vaccination at three and six weeks of age. Titers increased when these pigs were vaccinated at 12 weeks of age. There was no significant increase in mean titers of pigs from challenged sows following vaccination at 3, 6 and 12 weeks of age. Vaccinated pigs from control and vaccinated sows had a secondary response following challenge three weeks after vaccination.(ABSTRACT TRUNCATED AT 250 WORDS)     

Immunization of chickens and turkeys against avian influenza with monovalent and polyvalent oil emulsion vaccines.

Chickens and turkeys vaccinated with inactivated virus oil-emulsion vaccines containing different concentrations of either 1 (monovalent) or 4 (polyvalent) strains of avian influenza virus (AIV) were challenged-exposed with virulent AIV A/chicken/Scotland/59 or A/turkey/Ontario/7732/66. Four of 6 vaccines protected completely against postexposure mortality. Vaccine valency did not alter the serologic and challenge-exposure responses of chickens vaccinated with AIV A/turkey/Wisconsin/68, which was the virus component common to both monovalent and polyvalent vaccines. The magnitude of the serologic responses and protection against challenge-exposure were dependent on the concentration of virus in the vaccines. These data indicate that control of virulent AIV in chickens and turkeys by vaccination with inactivated vaccines may be feasible.     

The use of different vaccination schedules for sows to protect piglets against Aujeszky's disease

Several Aujeszky's disease virus (ADV) vaccination protocols of sows were evaluated with regard to the passive protection conferred on piglets in a recently built commercial farm. Three different groups of sows were vaccinated using a Bartha K-61 strain. One group received an inactivated vaccine during pregnancy and the other two groups received attenuated vaccines, either during pregnancy (day 65) or on the seventh day of lactation. At farrowing, sows vaccinated during lactation had lower seroneutralization titres than those vaccinated during pregnancy either with inactivated or attenuated vaccines. Accordingly, their piglets were the ones with lower levels of maternally transferred neutralizing antibodies. At 4 weeks of age, five piglets born of each group of sows were challenged intranasally with a neurotropic strain of ADV. Piglets born of sows vaccinated during pregnancy with inactivated and attenuated vaccines gained 1.50 kg bodyweight and 2.50 kg bodyweight during 7 days, respectively, and did not show clinical signs, while piglets from sows vaccinated during the previous lactation lost 0.60 kg and presented moderate to severe clinical signs of ADV. Vaccination of sows during pregnancy provided more protection against ADV for piglets than sow vaccination before mating. Piglets born from sows vaccinated with attenuated or inactivated vaccines did not present remarkable differences on protection.     

Transmission of classical swine fever virus by artificial insemination.

Classical swine fever (CSF) virus was introduced into an artificial insemination centre during the CSF epizootic of 1997-1998 in the Netherlands. The risk of further spread of CSF virus via contaminated semen was recognised, but could not be assessed because scientific data on this issue were not available. An animal experiment was performed to determine whether CSF virus could be transmitted via artificial insemination with contaminated semen. Three boars were inoculated with a CSF virus field isolate and from Day 5 till Day 18 thereafter, ejaculates were collected and prepared for insemination. Ruttish sows were inseminated with the extended semen from Day 5 till Day 18 after inoculation of the boars. All the inoculated boars remained healthy throughout the experiment and developed CSF neutralising antibodies between 14 and 21 days after inoculation. Virus was isolated from several semen samples collected from 5 till 11 days after inoculation. Two out of six sows inseminated with CSF contaminated semen seroconverted after insemination. All the other sows remained seronegative. In the foetuses of both the seropositive sows, CSF virus was detected at approximately 35 days post insemination. These results demonstrate that adult boars infected with CSF virus can excrete virus with semen and can, subsequently, transmit the virus to sows and their foetuses via artificial insemination.